Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ProPhase Labs Inc (PRPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.8
1 Year Target Price $13.8
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.22% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.26M USD | Price to earnings Ratio - | 1Y Target Price 13.8 |
Price to earnings Ratio - | 1Y Target Price 13.8 | ||
Volume (30-day avg) 1 | Beta -0.41 | 52 Weeks Range 0.22 - 4.03 | Updated Date 06/30/2025 |
52 Weeks Range 0.22 - 4.03 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -255.98% |
Management Effectiveness
Return on Assets (TTM) -30.92% | Return on Equity (TTM) -162.3% |
Valuation
Trailing PE - | Forward PE 10.09 | Enterprise Value 29696349 | Price to Sales(TTM) 2.78 |
Enterprise Value 29696349 | Price to Sales(TTM) 2.78 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 41541200 | Shares Floating 38222063 |
Shares Outstanding 41541200 | Shares Floating 38222063 | ||
Percent Insiders 7.99 | Percent Institutions 12.14 |
Analyst Ratings
Rating 1 | Target Price 13.8 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ProPhase Labs Inc
Company Overview
History and Background
ProPhase Labs Inc, formerly known as the Golden Cup Mining Corp. and Vaxinnate Corp., has evolved from mining operations to focusing on healthcare and diagnostics. It has expanded its offerings through strategic acquisitions and organic growth, with a focus on point-of-care diagnostics and CLIA lab services.
Core Business Areas
- Diagnostic Services: Offers COVID-19 testing and other diagnostic services through its CLIA-certified laboratory. This includes PCR testing, antibody testing, and other related services.
- Consumer Healthcare Products: Manufactures and markets over-the-counter (OTC) healthcare products, including Cold-EEZE cold remedy lozenges and cough drops.
- BE-WELL Health: A network marketing business focused on selling health and wellness products.
Leadership and Structure
Ted Karkus serves as the Chief Executive Officer and Chairman of the Board. The company has a board of directors and various management positions overseeing different aspects of the business, including diagnostics, consumer products, and sales.
Top Products and Market Share
Key Offerings
- Cold-EEZE: Cold-EEZE cold remedy lozenges and cough drops. While specific market share data is difficult to pinpoint due to the fragmented OTC cold remedy market, it is a recognized brand in the category. Competitors include Zicam, Airborne, and generic zinc lozenges. Revenue from this product is not publicly broken out from overall sales figures.
- COVID-19 Testing Services: Provides PCR and antibody testing services. The market share for COVID-19 testing has decreased significantly since the peak of the pandemic. Competition includes large diagnostic labs such as Labcorp and Quest Diagnostics, as well as smaller regional testing centers. Revenue from this service is not publicly broken out.
- BE-WELL Health Products: BE-WELL offers a variety of health and wellness products. Specific market share data is unavailable, but the nutraceutical market is very competitive. Competitors are similar to that of publicly held Herbalife Nutrition (HLF) and USANA Health Sciences (USNA)
Market Dynamics
Industry Overview
The healthcare and diagnostics industry is characterized by rapid technological advancements, evolving regulatory landscapes, and increasing demand for personalized medicine. The OTC healthcare product market is mature and highly competitive.
Positioning
ProPhase Labs is positioned as a provider of both diagnostic services and consumer healthcare products. Its competitive advantages include its established brand recognition for Cold-EEZE and its CLIA-certified laboratory. Challenges include competition from larger players and evolving market dynamics in the COVID-19 testing space.
Total Addressable Market (TAM)
The total addressable market includes the OTC cold and cough remedy market (estimated at billions of dollars globally) and the diagnostics market, which is also substantial. ProPhase's positioning within these markets allows it to capture a portion of the overall TAM, but its specific market share is difficult to quantify precisely.
Upturn SWOT Analysis
Strengths
- Established brand recognition for Cold-EEZE
- CLIA-certified laboratory for diagnostic services
- Vertically integrated manufacturing capabilities
Weaknesses
- High dependence on a limited number of products
- Competition from larger players with greater resources
- Volatility in demand for COVID-19 testing
- Historically inconsistent profitability
Opportunities
- Expansion of diagnostic services to include other types of testing
- Development of new consumer healthcare products
- Strategic acquisitions to broaden product portfolio
- Increased focus on BE-WELL health and wellness products.
Threats
- Increased competition from existing and new market entrants
- Changes in regulatory landscape affecting diagnostic testing
- Fluctuations in consumer demand for cold remedies
- Economic downturn impacting consumer spending
Competitors and Market Share
Key Competitors
- LH
- DGX
- HLF
- USNA
Competitive Landscape
ProPhase Labs faces significant competition from larger, more established players in both the diagnostics and OTC healthcare markets. Its strengths lie in its Cold-EEZE brand recognition and its CLIA lab. The company needs to innovate and differentiate to maintain a competitive edge.
Major Acquisitions
TK Consulting Services LLC
- Year: 2020
- Acquisition Price (USD millions): 1.1
- Strategic Rationale: The acquisition of TK Consulting Services LLC provided ProPhase with additional expertise and resources in the areas of clinical testing and laboratory operations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been influenced by the demand for COVID-19 testing and sales of Cold-EEZE.
Future Projections: Future growth projections depend on factors such as the expansion of diagnostic services, the success of new product launches, and the overall economic environment.
Recent Initiatives: Recent initiatives include expanding the diagnostic services offerings, focusing on BE-WELL and growing revenue through the health and wellness vertical.
Summary
ProPhase Labs operates in competitive healthcare markets. Its strengths include Cold-EEZE and diagnostics capabilities, but it faces challenges from larger players. Expansion of diagnostic services, new product development, and strategic acquisitions are crucial for future growth. It needs to carefully manage its capital and adapt to changing market conditions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), Company Website, Press Releases, Market Research Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProPhase Labs Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 1997-01-16 | Chairman & CEO Mr. Ted William Karkus | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 96 | Website https://www.prophaselabs.com |
Full time employees 96 | Website https://www.prophaselabs.com | ||
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.